Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 2, 2013, Pages 160-166

  Jacob, Robert F ^a   Walter, Mary F ^b   Self Medlin, Yehudi ^a   Mason, R Preston ^a,c  

^a ELUCIDA RESEARCH LLC   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atorvastatin metabolite; cholesterol; lipoprotein; oxidation; sdLDL

Indexed keywords

ATORVASTATIN; COPPER; LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; DOSE RESPONSE; HUMAN; LIPID OXIDATION; LIPID VESICLE; METABOLITE; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY; ULTRACENTRIFUGATION;

ANTIOXIDANTS; COPPER SULFATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDES; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIPOSOMES; OSMOLAR CONCENTRATION; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICOCHEMICAL PHENOMENA; PRODRUGS; PYRROLES; ULTRACENTRIFUGATION; UNILAMELLAR LIPOSOMES;

EID: 84883301790     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318294998d     Document Type: Article

References (46)

1. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
2. Steinberg D, Lewis A. Conner Memorial Lecture: oxidative modification of LDL and atherogenesis. Circulation. 1997;95:1062-1071.
3. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
4. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53:1068-1073.
5. Walter MF, Jacob RF, Jeffers B, et al. Serum levels of TBARS predict cardiovascular events in patients with stable coronary artery disease: A longitudinal analysis of the PREVENT study. J Am Coll Cardiol. 2004;44:1996-2002.
6. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006;99:1-14.
7. Ai M, Otokozawa S, Asztalos BF, et al. Small dense LDL cholesterol and coronary heart disease: Results from the Framingham Offspring Study. Clin Chem. 2010;56:967-976.
8. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996;276:875-881.
9. Hirano T, Ito Y, Koba S, et al. Clinical significance of small dense lowdensity lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol. 2004;24:558-563.
10. Koba S, Hirano T, Ito Y, et al. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis. 2006;189:206-214.
11. Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: Atherosclerosis and insulin resistance study. Metabolism. 2003;52:1612-1614.
12. Anber V, Griffin BA, McConnell M, et al. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996;124: 261-271.
13. Galeano NF, Al-Haideri M, Keyserman F, et al. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity. J Lipid Res. 1998;39:1263-1273.
14. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5:339-349.
15. Nigon F, Lesnik P, Rouis M, et al. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res. 1991;32:1741-1753.
16. de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 1991;11:298-306.
17. Tribble DL, Holl LG, Wood PD, et al. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189-199.
18. Bahadir MA, Oguz A, Uzunlulu M, et al. Effects of different statin treatments on small dense low-density lipoprotein in patients with metabolic syndrome. J Atheroscler Thromb. 2009;16:684-690.
19. Fukushima Y, Hirayama S, Ueno T, et al. Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clin Chim Acta. 2011;412:1423-1427.
20. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 1999;25:199-211.
21. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14:128-132.
22. Davignon J, Jacob RF, Mason RP. The antioxidant effects of statins. Coron Artery Dis. 2004;15:251-258.
23. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
24. Mason RP, Walter MF, Day CA, et al. Intermolecular differences for HMG-CoA reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005;96:11F-23F.
25. Kinlay S, Schwartz GG, Olsson AG, et al. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008;28:142-147.
26. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: Role of microdomains and oxidative stress. Circulation. 2004;109:II34-II41.
27. Mason RP, Walter MF, Day CA, et al. Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J Biol Chem. 2006;281:9337-9345.
28. Aviram M, Rosenblat M, Bisgaier CL, et al. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis. 1998;138:271-280.
29. El-Saadani M, Esterbauer H, El-Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using commercially available reagent. J Lipid Res. 1989;30:627-630.
30. Innis-Whitehouse W, Li X, Brown WV, et al. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res. 1998;39:679-690.
31. Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105: 328-331.
32. Mak IT, Weglicki WB. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol. 1994;234:620-630.
33. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238-252.
34. Szoka F, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9:467-508.
35. Li QT, Yeo MH, Tan BK. Lipid peroxidation in small and large phospholipid unilamellar vesicles induced by water-soluble free radical sources. Biochem Biophys Res Commun. 2000;273:72-76.
36. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141-1160.
37. Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, lowdensity lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94:350-356.
38. Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med. 2001;110:103-110.
39. Lee C, Sigari F, Segrado T, et al. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-Activating factor acetylhydrolase. Arterioscler Thromb Vasc Biol. 1999;19:1437-1446.
40. Walter MF, Jacob RF, Bjork RE, et al. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: The PREVENT study. J Am Coll Cardiol. 2008;51:1196-1202.
41. Sever PS, Dahlof B, Poulter NR, et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens. 2001;19:1139-1147.
42. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipidlowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trail. Eur Heart J. 2006;27:2982-2988.
43. Singh U, Devaraj S, Jialal I, et al. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008;102:321-325.
44. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110:1406-1412.
45. Sezer ED, Sozmen EY, Nart D, et al. Effect of atorvastatin therapy on oxidant-Antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag. 2011;7:333-343.
46. Shishehbor MH, Brenna ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426-431.